AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 92 min read$LLY

Eli Lilly's Dual Therapy Shows Promise in Psoriasis and Metaboli

Eli Lilly's phase 3b TOGETHER-PsO trial showed its combination treatment of Taltz and Zepbound improved outcomes for patients with moderate-to-severe plaque psoriasis who are overweight or obese. The company's GF Value™ suggests it is modestly undervalued with a 25.4% margin of safety, and its GF Score™ is 98 out of 100, indicating strong financial health. Insiders have been net sellers, while 25 premium gurus hold LLY, with 12 adding and 10 trimming positions.

Original reporting
gurufocus.com
Published Oct 9, 2026, 3:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 4:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$LLY
Bullish
high confidence
Mentioned
$LLY
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$LLYBullishMed
01

Why it matters

The data may broaden the addressable market for both Taltz and Zepbound, supporting future sales growth.

02

Market read

First disclosure of promising trial results could move LLY stock and affect biotech sector sentiment.

03

What to watch

Insider selling and valuation concerns could temper enthusiasm despite positive data.

Relevance 7/10Novelty 9/10Timing: today

Background

Eli Lilly announced new combination therapy data for psoriasis patients who are overweight or obese.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Phase 3b TOGETHER-PsO trial shows the Taltz + Zepbound combo improves psoriasis and metabolic biomarkers versus Taltz alone.

Expected impact

likely upside as investors price in broader indication potential

Evidence & confidence

First report of significant efficacy in a new indication; market typically reacts favorably to such data.

Market effects

Sector

could boost biotech/pharma sector sentiment on dermatology and metabolic therapies

Regional

U.S. biotech stocks may see modest gains

Global

potentially influences global pharma pipelines targeting obesity‑related skin conditions

Counterpoint

What could challenge this read

Trial size and long‑term safety remain uncertain; investors may wait for Phase 3 confirmatory data.

Key entities

  • company
    Eli Lilly

    Pharmaceutical company reporting trial results.

  • drug
    Taltz

    Ixekizumab, an immunology drug.

  • drug
    Zepbound

    Tirzepatide, a metabolic agent.

Read at source← All news

StoryEli Lilly reports broader biomarker changes with Taltz‑Zepbound combo in psoriasis‑obesity trial

Also covered by

4 outlets

Related articles

OCT 9
$LLYMed

Eli Lilly And Company Announces New Exploratory Phase 3b Data On Taltz And Zepbound In Adults With Psoriasis And Obesity

Eli Lilly presented data from the TOGETHER-PsO Phase 3b trial showing that combining Taltz (ixekizumab) and Zepbound (tirzepatide) led to broader biomarker responses in adults with psoriasis and obesity compared to Taltz alone. The trial, presented at the 2026 Fall Clinical Dermatology Conference, found greater reductions in inflammatory immune activity with the combination treatment.

marketscreener.com2 min
OCT 9
$LLYMed

New data for Eli Lilly and the Taltz-Zepbound combination

Eli Lilly presented new data from a Phase 3b trial showing that the combination of Taltz and Zepbound may benefit obese or overweight psoriasis patients. The company claims the results support a more integrated treatment approach for these patients, addressing both immunological and metabolic aspects. According to Lilly, psoriasis and obesity often coexist in 61% of U.S. patients.

marketscreener.com2 min
OCT 9
$LLYMedAI 9/10

New Weight-Loss Drug Helps People With Type 2 Diabetes Lose 21% of Their Body Weight

Eli Lilly's experimental drug, retatrutide, helped Type 2 diabetes patients lose 20.8% of their body weight in an 80-week trial. The highest dose group saw an average weight reduction of 49.6 pounds. The drug also improved blood sugar control, with 40% of participants on the two highest doses achieving normal blood sugar levels. The results were presented at the European Association for the Study of Diabetes meeting and published in The Lancet.

zmescience.com2 min
OCT 9
$LLYMedAI 8/10

Lilly Highlights Immune And Metabolic Effects Of Taltz Plus Zepbound

Eli Lilly reported Phase 3b data showing combined Taltz and Zepbound treatment led to broader changes in psoriasis-related, immune, and metabolic biomarkers compared to Taltz alone. The study involved adults with psoriasis and obesity or overweight. LLY closed at $1,169.60, down 1.61%, and is down 0.51% in pre-market trading.

rttnews.com2 min